Best Strategy for Acute MI and Multivessel Disease

Best Strategy for Acute MI and Multivessel DiseaseThe goal of this study was to assess all available revascularization strategies for patients undergoing ST elevation acute myocardial infarction and multivessel disease.

 

Among the strategies to treat this group of patients, there were:

  • culprit vessel intervention only,
  • culprit vessel intervention and, in case of success, multivessel intervention,
  • culprit vessel intervention with staged revascularization, within the same hospitalization period.

 

These three strategies were compared in 6,503 patients with STEMI and multivessel disease enrolled in the British Columbia registry between 2008 and 2014. The study assessed all-cause mortality and repeat revascularization at 2 years.

 

Both culprit vessel intervention (HR: 0.78; CI 95%: 0.64 to 0.97; p=0.023) and staged revascularization (HR: 0.55; CI 95%: 0.36 to 0.82; p=0.004) showed lower mortality when compared to multivessel intervention at primary PCI.

 

Culprit vessel intervention only showed higher repeat revascularization rate when compared with multivessel intervention (HR: 1.25; CI 95%: 1.02 to 1.54; p=0.036) and staged revascularization (HR: 0.64; CI 95%: 0.46 to 0.90; p=0.012).

 

Conclusion

In patients undergoing ST elevation acute myocardial infarction with multivessel disease, culprit vessel intervention followed by staged multivessel revascularization showed lower mortality and repeat revascularization rates. These findings call for a prospective evaluation of randomized studies with adequate statistical power.

 

Editorial Comment

Both strategies of culprit vessel intervention (with or without following multivessel intervention) were associated to lower mortality compared to multivessel intervention, as long as the non-culprit arteries were the right coronary and left circumflex arteries.

 

Revascularization of the non-culprit left anterior descending artery at primary PCI did show the same benefits.

 

Original Title: Culprit Vessel versus Multivessel versus In-Hospital Staged Intervention for Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease. Stratified Analyses in High-Risk Patient Groups and Anatomic Subsets of Non-culprit Disease.

Reference: M. Bilal Iqbal et al. J Am Coll Cardiol Intv 2017;10:11–23.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....